undamentalytics Newsletter
Sign in

Urogen Pharma Ltd. cash flow statement

In fiscal 2025, Urogen Pharma Ltd.'s operations generated −$162m of cash; it spent $289,000 on capital projects, leaving free cash flow of −$163m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations4−10−37−71−106−85−88−76−97−162−159
Depreciation and amortisation00000111000
Stock-based pay2631302823119131216
Capital spending10101100000
Free cash flow3−10−38−71−107−86−88−77−97−163−159
Free cash flow after stock pay2−16−69−101−135−109−98−86−110−175−175
Shares issued—616416216006715140—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABUS vs URGNURGN vs VALNNUVB vs URGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Urogen Pharma Ltd.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Urogen Pharma Ltd.